AI assistant
AMICUS THERAPEUTICS, INC. — Director's Dealing 2020
Jan 17, 2020
31523_dirs_2020-01-17_1cfeb6ec-6911-4d61-bd22-c37c19a5caee.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AMICUS THERAPEUTICS, INC. (FOLD)
CIK: 0001178879
Period of Report: 2020-01-15
Reporting Person: Rosenberg Ellen (Chief Legal Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-01-15 | Common Stock | S | 22100 | $10.3458 | Disposed | 185350 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 15000 | Indirect |
Footnotes
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $9.90 to $10.51. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.